Patient-Reported Outcome (PRO) as an Addition to Long-Term Results after High-Precision Stereotactic Radiotherapy in Patients with Secreting and Non-Secreting Pituitary Adenomas: A Retrospective Cohort Study up to 17-Years Follow-Up
Abstract
:1. Introduction
2. Patients and Methods
2.1. Patients
2.2. Treatment
2.3. Follow-Up and Patient-Reported Outcome (PRO)
2.4. Statistics
3. Results
3.1. Outcome
3.2. Toxicity
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Gsponer, J.; De Tribolet, N.; Deruaz, J.P.; Janzer, R.; Uske, A.; Mirimanoff, R.O.; Reymond, M.J.; Rey, F.; Temler, E.; Gaillard, R.C.; et al. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients. Medicine 1999, 78, 236–269. [Google Scholar] [CrossRef] [PubMed]
- Saeger, W.; Ludecke, D.K.; Buchfelder, M.; Fahlbusch, R.; Quabbe, H.J.; Petersenn, S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur. J. Endocrinol. 2007, 156, 203–216. [Google Scholar] [CrossRef] [PubMed]
- Cortet-Rudelli, C.; Bonneville, J.F.; Borson-Chazot, F.; Clavier, L.; Coche Dequeant, B.; Desailloud, R.; Maiter, D.; Rohmer, V.; Sadoul, J.L.; Sonnet, E.; et al. Post-surgical management of non-functioning pituitary adenoma. Ann. Endocrinol. 2015, 76, 228–238. [Google Scholar] [CrossRef]
- Freda, P.U.; Beckers, A.M.; Katznelson, L.; Molitch, M.E.; Montori, V.M.; Post, K.D.; Vance, M.L.; Endocrine, S. Pituitary incidentaloma: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011, 96, 894–904. [Google Scholar] [CrossRef] [PubMed]
- Aflorei, E.D.; Korbonits, M. Epidemiology and etiopathogenesis of pituitary adenomas. J. Neuro Oncol. 2014, 117, 379–394. [Google Scholar] [CrossRef]
- Gondim, J.A.; de Almeida, J.P.; de Albuquerque, L.A.; Schops, M.; Gomes, E.; Ferraz, T. Headache associated with pituitary tumors. J. Headache Pain 2009, 10, 15–20. [Google Scholar] [CrossRef]
- Chen, L.; White, W.L.; Spetzler, R.F.; Xu, B. A prospective study of nonfunctioning pituitary adenomas: Presentation, management, and clinical outcome. J. Neuro Oncol. 2011, 102, 129–138. [Google Scholar] [CrossRef]
- Kaltsas, G.A.; Nomikos, P.; Kontogeorgos, G.; Buchfelder, M.; Grossman, A.B. Clinical review: Diagnosis and management of pituitary carcinomas. J. Clin. Endocrinol. Metab. 2005, 90, 3089–3099. [Google Scholar] [CrossRef]
- Sun, D.Q.; Cheng, J.J.; Frazier, J.L.; Batra, S.; Wand, G.; Kleinberg, L.R.; Rigamonti, D.; Quinones-Hinojosa, A.; Salvatori, R.; Lim, M. Treatment of pituitary adenomas using radiosurgery and radiotherapy: A single center experience and review of literature. Neurosurg. Rev. 2010, 34, 181–189. [Google Scholar] [CrossRef]
- Rieken, S.; Habermehl, D.; Welzel, T.; Mohr, A.; Lindel, K.; Debus, J.; Combs, S.E. Long term toxicity and prognostic factors of radiation therapy for secreting and non-secreting pituitary adenomas. Radiat. Oncol. 2013, 8, 18. [Google Scholar] [CrossRef]
- Buchfelder, M.; Schlaffer, S.M.; Zhao, Y. The optimal surgical techniques for pituitary tumors. Best Pract. Res. Clin. Endocrinol. Metab. 2019, 33, 101299. [Google Scholar] [CrossRef] [PubMed]
- Klibanski, A. Clinical practice. Prolactinomas. N. Engl. J. Med. 2010, 362, 1219–1226. [Google Scholar] [CrossRef] [PubMed]
- Swearingen, B.; Barker, F.G., 2nd; Katznelson, L.; Biller, B.M.; Grinspoon, S.; Klibanski, A.; Moayeri, N.; Black, P.M.; Zervas, N.T. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab. 1998, 83, 3419–3426. [Google Scholar] [CrossRef] [PubMed]
- Solari, D.; Cavallo, L.M.; Cappabianca, P. Surgical approach to pituitary tumors. Handb. Clin. Neurol. 2014, 124, 291–301. [Google Scholar] [CrossRef]
- Baldwin, J.L.; Singh, H.; Sittig, D.F.; Giardina, T.D. Patient portals and health apps: Pitfalls, promises, and what one might learn from the other. Healthcare 2017, 5, 81–85. [Google Scholar] [CrossRef]
- Varlamov, E.V.; McCartney, S.; Fleseriu, M. Functioning Pituitary Adenomas—Current Treatment Options and Emerging Medical Therapies. Eur. Endocrinol. 2019, 15, 30–40. [Google Scholar] [CrossRef]
- Sun, S.; Liu, A. Long-term follow-up studies of Gamma Knife surgery with a low margin dose for vestibular schwannoma. J. Neurosurg. 2012, 117, 57–62. [Google Scholar] [CrossRef]
- Langsenlehner, T.; Stiegler, C.; Quehenberger, F.; Feigl, G.C.; Jakse, G.; Mokry, M.; Langsenlehner, U.; Kapp, K.S.; Mayer, R. Long-term follow-up of patients with pituitary macroadenomas after postoperative radiation therapy: Analysis of tumor control and functional outcome. Strahlenther. Onkol. 2007, 183, 241–247. [Google Scholar] [CrossRef]
- Kong, D.S.; Kim, Y.H.; Kim, Y.H.; Hur, K.Y.; Kim, J.H.; Kim, M.S.; Paek, S.H.; Kwon, D.H.; Kim, D.K.; Lee, J.I. Long-Term Efficacy and Tolerability of Gamma Knife Radiosurgery for Growth Hormone-Secreting Adenoma: A Retrospective Multicenter Study (MERGE-001). World Neurosurg. 2019, 122, e1291–e1299. [Google Scholar] [CrossRef]
- Weber, D.C.; Momjian, S.; Pralong, F.P.; Meyer, P.; Villemure, J.G.; Pica, A. Adjuvant or radical fractionated stereotactic radiotherapy for patients with pituitary functional and nonfunctional macroadenoma. Radiat. Oncol. 2011, 6, 169. [Google Scholar] [CrossRef]
- Hiniker, S.M.; Modlin, L.A.; Choi, C.Y.; Atalar, B.; Seiger, K.; Binkley, M.S.; Harris, J.P.; Liao, Y.J.; Fischbein, N.; Wang, L.; et al. Dose-Response Modeling of the Visual Pathway Tolerance to Single-Fraction and Hypofractionated Stereotactic Radiosurgery. Semin. Radiat. Oncol. 2016, 26, 97–104. [Google Scholar] [CrossRef] [PubMed]
- Cordeiro, D.; Xu, Z.; Mehta, G.U.; Ding, D.; Vance, M.L.; Kano, H.; Sisterson, N.; Yang, H.C.; Kondziolka, D.; Lunsford, L.D.; et al. Hypopituitarism after Gamma Knife radiosurgery for pituitary adenomas: A multicenter, international study. J. Neurosurg. 2018. [Google Scholar] [CrossRef] [PubMed]
- Sun, S.; Liu, A.; Zhang, Y. Long-Term Follow-Up Studies of Gamma Knife Radiosurgery for Postsurgical Nonfunctioning Pituitary Adenomas. World Neurosurg. 2019. [Google Scholar] [CrossRef] [PubMed]
- Petit, J.H.; Biller, B.M.; Yock, T.I.; Swearingen, B.; Coen, J.J.; Chapman, P.; Ancukiewicz, M.; Bussiere, M.; Klibanski, A.; Loeffler, J.S. Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J. Clin. Endocrinol. Metab. 2008, 93, 393–399. [Google Scholar] [CrossRef] [PubMed]
- Wattson, D.A.; Tanguturi, S.K.; Spiegel, D.Y.; Niemierko, A.; Biller, B.M.; Nachtigall, L.B.; Bussiere, M.R.; Swearingen, B.; Chapman, P.H.; Loeffler, J.S.; et al. Outcomes of proton therapy for patients with functional pituitary adenomas. Int. J. Radiat. Oncol. Biol. Phys. 2014, 90, 532–539. [Google Scholar] [CrossRef] [PubMed]
- Ronson, B.B.; Schulte, R.W.; Han, K.P.; Loredo, L.N.; Slater, J.M.; Slater, J.D. Fractionated proton beam irradiation of pituitary adenomas. Int. J. Radiat. Oncol. Biol. Phys. 2006, 64, 425–434. [Google Scholar] [CrossRef]
- Kessel, K.A.; Fischer, H.; Oechnser, M.; Zimmer, C.; Meyer, B.; Combs, S.E. High-precision radiotherapy for meningiomas: Long-term results and patient-reported outcome (PRO). Strahlenther. Onkol. 2017, 193, 921–930. [Google Scholar] [CrossRef]
- Kessel, K.A.; Fischer, H.; Vogel, M.M.; Oechsner, M.; Bier, H.; Meyer, B.; Combs, S.E. Fractionated vs. single-fraction stereotactic radiotherapy in patients with vestibular schwannoma: Hearing preservation and patients’ self-reported outcome based on an established questionnaire. Strahlenther. Onkol. 2017, 193, 192–199. [Google Scholar] [CrossRef]
- Kessel, K.A.; Vogel, M.M.; Alles, A.; Dobiasch, S.; Fischer, H.; Combs, S.E. Mobile App Delivery of the EORTC QLQ-C30 Questionnaire to Assess Health-Related Quality of Life in Oncological Patients: Usability Study. JMIR Mhealth Uhealth 2018, 6, e45. [Google Scholar] [CrossRef]
- Kessel, K.A.; Vogel, M.M.; Kessel, C.; Bier, H.; Biedermann, T.; Friess, H.; Herschbach, P.; von Eisenhart-Rothe, R.; Meyer, B.; Kiechle, M.; et al. Mobile Health in Oncology: A Patient Survey About App-Assisted Cancer Care. JMIR Mhealth Uhealth 2017, 5, e81. [Google Scholar] [CrossRef]
- Kessel, K.A.; Vogel, M.M.E.; Schmidt-Graf, F.; Combs, S.E. Mobile Apps in Oncology: A Survey on Health Care Professionals’ Attitude Toward Telemedicine, mHealth, and Oncological Apps. J. Med. Internet Res. 2016, 18, e312. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oruckaptan, H.H.; Senmevsim, O.; Ozcan, O.E.; Ozgen, T. Pituitary adenomas: Results of 684 surgically treated patients and review of the literature. Surg. Neurol. 2000, 53, 211–219. [Google Scholar] [CrossRef]
- Isobe, K.; Ohta, M.; Yasuda, S.; Uno, T.; Hara, R.; Machida, N.; Saeki, N.; Yamaura, A.; Shigematsu, N.; Ito, H. Postoperative radiation therapy for pituitary adenoma. J. Neuro Oncol. 2000, 48, 135–140. [Google Scholar] [CrossRef] [PubMed]
- van Beek, A.P.; van den Bergh, A.C.; van den Berg, L.M.; van den Berg, G.; Keers, J.C.; Langendijk, J.A.; Wolffenbuttel, B.H. Radiotherapy is not associated with reduced quality of life and cognitive function in patients treated for nonfunctioning pituitary adenoma. Int. J. Radiat. Oncol. Biol. Phys. 2007, 68, 986–991. [Google Scholar] [CrossRef]
- Hung, Y.C.; Lee, C.C.; Yang, H.C.; Mohammed, N.; Kearns, K.N.; Nabeel, A.M.; Abdel Karim, K.; Emad Eldin, R.M.; El-Shehaby, A.M.N.; Reda, W.A.; et al. The benefit and risk of stereotactic radiosurgery for prolactinomas: An international multicenter cohort study. J. Neurosurg. 2019. [Google Scholar] [CrossRef]
- Shrieve, D.C.; Hazard, L.; Boucher, K.; Jensen, R.L. Dose fractionation in stereotactic radiotherapy for parasellar meningiomas: Radiobiological considerations of efficacy and optic nerve tolerance. J. Neurosurg. 2004, 101 (Suppl. 3), 390–395. [Google Scholar] [CrossRef]
- Stafford, S.L.; Perry, A.; Suman, V.J.; Meyer, F.B.; Scheithauer, B.W.; Lohse, C.M.; Shaw, E.G. Primarily resected meningiomas: Outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin. Proc. 1998, 73, 936–942. [Google Scholar] [CrossRef]
- Xiang, M.; Chan, C.; Wang, L.; Jani, K.; Holdsworth, S.J.; Iv, M.; Pollom, E.L.; Soltys, S.G. Physiological motion of the optic chiasm and its impact on stereotactic radiosurgery dose. Br. J. Radiol. 2019, 92, 20190170. [Google Scholar] [CrossRef]
- Denis, F.; Lethrosne, C.; Pourel, N.; Molinier, O.; Pointreau, Y.; Domont, J.; Bourgeois, H.; Senellart, H.; Tremolieres, P.; Lizee, T.; et al. Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients. J. Natl. Cancer Inst. 2017, 109. [Google Scholar] [CrossRef] [Green Version]
- Basch, E.; Deal, A.M.; Dueck, A.C.; Scher, H.I.; Kris, M.G.; Hudis, C.; Schrag, D. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA 2017, 318, 197–198. [Google Scholar] [CrossRef] [Green Version]
- Atkinson, T.M.; Ryan, S.J.; Bennett, A.V.; Stover, A.M.; Saracino, R.M.; Rogak, L.J.; Jewell, S.T.; Matsoukas, K.; Li, Y.; Basch, E. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): A systematic review. Supportive Care Cancer 2016, 24, 3669–3676. [Google Scholar] [CrossRef] [Green Version]
- Christodoulou, M.; McCloskey, P.; Stones, N.; Bayman, N.; Burt, P.; Chittalia, A.; Harris, M.; Lee, L.; Pemberton, L.; Sheikh, H.; et al. Investigation of a Patient Reported Outcome tool to assess radiotherapy-related toxicity prospectively in patients with lung cancer. Radiother. Oncol. 2014, 112, 244–249. [Google Scholar] [CrossRef] [PubMed]
- Basch, E.; Reeve, B.B.; Mitchell, S.A.; Clauser, S.B.; Minasian, L.M.; Dueck, A.C.; Mendoza, T.R.; Hay, J.; Atkinson, T.M.; Abernethy, A.P.; et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J. Natl. Cancer Inst. 2014, 106, dju244. [Google Scholar] [CrossRef] [PubMed]
- Dueck, A.C.; Mendoza, T.R.; Mitchell, S.A.; Reeve, B.B.; Castro, K.M.; Rogak, L.J.; Atkinson, T.M.; Bennett, A.V.; Denicoff, A.M.; O’Mara, A.M.; et al. Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol. 2015, 1, 1051–1059. [Google Scholar] [CrossRef] [PubMed]
- Fan, Y.; Jiang, S.; Hua, M.; Feng, S.; Feng, M.; Wang, R. Machine Learning-Based Radiomics Predicts Radiotherapeutic Response in Patients With Acromegaly. Front. Endocrinol. 2019, 10, 588. [Google Scholar] [CrossRef] [Green Version]
Characteristic | Specification | N (%) | Median (Range) |
---|---|---|---|
Gender | Female | 30 (44%) | |
Male | 39 (56%) | ||
Age at RT [years] | 61 (28–87) | ||
Size | Macroadenoma | 66 (96%) | |
Microadenoma | 3 (4%) | ||
Immunohistochemical classification | PRL | 7 (10%) | |
GH | 5 (7%) | ||
ACTH | 5 (7%) | ||
PRL & GH | 2 (3%) | ||
FSH | 2 (3%) | ||
TSH | 1 (1%) | ||
Non-functioning | 47 (68%) | ||
RT type | Primary treatment | 12 (17%) | |
Salvage treatment | 57 (83%) | ||
PTV [mL] | 21.0 (1.9–124.5) | ||
Total dose [Gy] | 50.4 (45–54) |
Outcome | 3-year | 5-year | 8-year | 10-year | 15-year |
---|---|---|---|---|---|
OS | 95% | 90% | 86% | 79% | 65% |
LC | 97% | 92% | 87% | 87% | 87% |
CTCAE Grade | PRE RT | <6 Months | >6 Months to <24 Months | >2 Years | PRO | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n = 69 | n = 58 | n = 47 | n = 57 | n = 20 | |||||||||||||||
1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | |
Pain | - | - | - | - | 2 | - | - | - | 2 | 1 | - | - | 2 | 1 | - | - | 4 | 1 | - |
(3%) | (4%) | (2%) | (4%) | (2%) | (20%) | (5%) | |||||||||||||
Fatigue | - | - | - | - | 9 | 2 | - | - | 2 | - | - | - | 6 | 7 | - | - | 7 | 5 | 2 |
(16%) | (3%) | (4%) | (11%) | (12%) | (35%) | (25%) | (10%) | ||||||||||||
Nausea/vomiting | - | - | - | - | 1 | - | - | - | 1 | - | - | - | 2 | - | - | - | 1 | - | - |
(2%) | (2%) | (4%) | (5%) | ||||||||||||||||
Skin problems/erythema | - | - | - | - | 3 | - | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 |
(5%) | (5%) | (5%) | |||||||||||||||||
Edema | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | 1 | - | - |
(2%) | (2%) | (5%) | |||||||||||||||||
Sensory disorders | - | 1 | - | - | 5 | - | - | - | - | 2 | - | - | 1 | 5 | 1 | - | 1 | - | - |
(1%) | (9%) | (4%) | (2%) | (9%) | (2%) | (5%) | |||||||||||||
Motor disorders | 1 | 1 | - | - | 1 | 2 | - | - | 2 | - | - | - | 1 | 5 | - | - | 2 | - | 2 |
(1%) | (1%) | (2%) | (3%) | (4%) | (2%) | (9%) | (10%) | (10%) | |||||||||||
Weight loss | - | - | - | - | - | - | - | - | - | - | - | - | 1 | 2 | - | - | 3 | - | - |
(2%) | (4%) | (15%) | |||||||||||||||||
Seizures | - | - | - | - | 1 | - | - | - | - | - | - | - | 2 | 1 | - | - | 2 | - | - |
(2%) | (4%) | (2%) | (10%) | ||||||||||||||||
Headache | 5 | 3 | - | - | 8 | 1 | - | - | 5 | - | - | - | 4 | 1 | - | - | 4 | - | 1 |
(7%) | (4%) | (14%) | (2%) | (11%) | (7%) | (2%) | (20%) | (5%) | |||||||||||
Hair loss | - | - | - | - | 14 | - | - | - | - | - | - | - | - | - | - | - | 3 | 2 | - |
(24%) | (15%) | (10%) | |||||||||||||||||
Dizziness/vertigo | 3 | 1 | - | - | 8 | - | - | - | 1 | 2 | - | - | 1 | 3 | - | - | 3 | 2 | - |
(4%) | (1%) | (14%) | (2%) | (4%) | (2%) | (5%) | (15%) | (10%) | |||||||||||
Cognitive disorders | 1 | 1 | - | - | - | 1 | - | - | - | 1 | - | - | 6 | 4 | - | - | 5 | 1 | |
(1%) | (1%) | (2%) | (2%) | (11%) | (7%) | (25%) | (5%) | ||||||||||||
Trigeminal neuropathy | - | - | - | - | 1 | - | - | - | - | - | - | - | 1 | - | - | - | - | - | - |
(2%) | (2%) | ||||||||||||||||||
Facial neuropathy | 1 | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | - | - | - | - | - |
(1%) | (2%) | (2%) | |||||||||||||||||
Vision loss | 3 | 2 | - | 5 | 3 | 1 | - | - | - | 2 | 1 | -- | 2 | 5 | 2 | - | 5 | 2 | 3 |
(4%) | (3%) | (7%) | (5%) | (2%) | (4%) | (2%) | (4%) | (9%) | (4%) | (25%) | (10%) | (15%) | |||||||
Visual deficits | 11 | 8 | 3 | - | 5 | 3 | - | - | 1 | 1 | 1 | - | 1 | 3 | 1 | - | 3 | 1 | - |
(16%) | (12%) | (4%) | (9%) | (5%) | (2%) | (2%) | (2%) | (2%) | (5%) | (2%) | (15%) | (5%) | |||||||
Eye problems | 1 | 4 | - | - | 1 | - | - | - | 2 | 1 | - | - | 2 | 6 | - | - | 1 | - | - |
(1%) | (6%) | (2%) | (4%) | (2%) | (4%) | (11%) | (5%) | ||||||||||||
Smell/taste deficits | - | - | - | - | 1 | 2 | - | - | 1 | - | - | - | 2 | - | - | - | - | - | - |
(2%) | (3%) | (2%) | (4%) | ||||||||||||||||
Hypopituitarism | - | 35 | - | - | - | 3 | - | - | - | 2 | - | - | - | 6 | - | - | - | 1 | 1 |
(51%) | (5%) | (4%) | (11%) | (5%) | (5%) | ||||||||||||||
Pituitary gland hyperactivity | 2 | 5 | - | - | 1 | 1 | - | - | - | 1 | - | - | - | 2 | - | - | - | - | - |
(3%) | (7%) | (2%) | (2%) | (2%) | (4%) |
Symptom | Physician-Reported after RT | PRO | ||
---|---|---|---|---|
CTCAE Grade | 1/2 | 3 | 1/2 | 3 |
Pain | 6 | - | 5 | - |
(30%) | (25%) | |||
Fatigue | 8 | - | 12 | 2 |
(40%) | (60%) | (10%) | ||
Nausea/vomiting | 1 | - | 1 | - |
(5%) | (5%) | |||
Skin problems/erythema | 1 | - | 1 | 1 |
(5%) | (5%) | (5%) | ||
Edema | - | - | 1 | - |
(5%) | ||||
Sensory disorders | 3 | 1 | 1 | - |
(15%) | (5%) | (5%) | ||
Motor disorders | 2 | 2 | 2 | |
(10%) | (10%) | (10%) | ||
Weight loss | - | - | 3 | - |
(15%) | ||||
Seizures | 1 | - | 2 | - |
(5%) | (10%) | |||
Headache | 5 | - | 4 | 1 |
(25%) | (20%) | (5%) | ||
Hair loss | 7 | - | 5 | - |
(35%) | (25%) | |||
Dizziness/vertigo | 2 | - | 5 | - |
(10%) | (25%) | |||
Cognitive disorders | 1 | - | 6 | - |
(5%) | (30%) | |||
Trigeminal neuropathy | 2 | - | - | - |
(10%) | ||||
Facial neuropathy | - | - | - | - |
Vision loss | 3 | 1 | 7 | 3 |
(15%) | (5%) | (35%) | (15%) | |
Visual deficits | 5 | - | 4 | - |
(25%) | (20%) | |||
Eye problems | 4 | - | 1 | - |
(20%) | (5%) | |||
Smell/taste deficits | 1 | - | - | - |
(5%) | ||||
Hypopituitarism | 3 | - | 1 | 1 |
(15%) | (5%) | (5%) | ||
Pituitary gland hyperactivity | 1 | - | - | - |
(5%) |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kessel, K.A.; Diehl, C.D.; Oechsner, M.; Meyer, B.; Gempt, J.; Zimmer, C.; Schmidt-Graf, F.; Combs, S.E. Patient-Reported Outcome (PRO) as an Addition to Long-Term Results after High-Precision Stereotactic Radiotherapy in Patients with Secreting and Non-Secreting Pituitary Adenomas: A Retrospective Cohort Study up to 17-Years Follow-Up. Cancers 2019, 11, 1884. https://doi.org/10.3390/cancers11121884
Kessel KA, Diehl CD, Oechsner M, Meyer B, Gempt J, Zimmer C, Schmidt-Graf F, Combs SE. Patient-Reported Outcome (PRO) as an Addition to Long-Term Results after High-Precision Stereotactic Radiotherapy in Patients with Secreting and Non-Secreting Pituitary Adenomas: A Retrospective Cohort Study up to 17-Years Follow-Up. Cancers. 2019; 11(12):1884. https://doi.org/10.3390/cancers11121884
Chicago/Turabian StyleKessel, Kerstin A., Christian D. Diehl, Markus Oechsner, Bernhard Meyer, Jens Gempt, Claus Zimmer, Friederike Schmidt-Graf, and Stephanie E. Combs. 2019. "Patient-Reported Outcome (PRO) as an Addition to Long-Term Results after High-Precision Stereotactic Radiotherapy in Patients with Secreting and Non-Secreting Pituitary Adenomas: A Retrospective Cohort Study up to 17-Years Follow-Up" Cancers 11, no. 12: 1884. https://doi.org/10.3390/cancers11121884